ArticleClinical rheumatology2025
Clinical variables and lung ultrasonography for the screening of interstitial lung disease in patients with rheumatoid arthritis.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Divergent approaches to rheumatoid arthritis-associated interstitial lung disease: a comparative analysis of international clinical practice guidelines.Rheumatology international · 2026Review
- International evidence-based recommendations for point-of-care lung ultrasound : 2025 focused update of the 2012 recommendations.Intensive care medicine · 2026Article
- Diagnostic value of lung ultrasound in interstitial lung disease associated with rheumatoid arthritis: Correlation with HRCT and differentiation of ILD subtypes.Rheumatology and immunology research · 2026Article
- Advances in the Diagnosis and Treatment of Rheumatoid Arthritis: From Pathological Mechanisms to Integrated Chinese and Western Medicine Therapeutic Strategies.International journal of general medicine · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
The best screening way to detect interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) is still debated.
objectivesTo evaluate the performance of scores to identify patients with ILD in patients with RA.
methodsCross-sectional study, adult outpatients with RA were included and those with any disease that can affect lung ultrasonography (LUS) evaluation were excluded. Sociodemographic, clinical, and therapeutic variables were recorded. All patients underwent chest x-rays, pulmonary function tests (PFT), LUS, and high-resolution chest tomography (HRCT). Univariate and multivariate analyses and ROC curves.
results107 patients with RA, median age of 62 years (IQR 36-84), 82.2% female, and median disease duration 14 years (IQR 1-42). A total of 30 patients (29.5%) had ILD by HRCT. The classic cutoff value of ≥ 5 B lines in the LUS (ILD by HRCT as the gold standard) showed an AUC of 0.86 (95% CI 0.78-0.94), Se 87.1%, and Sp 74.3% for the detection of ILD. A clinical score made up of 5 variables to identify the presence of ILD, based on the strength of association in the multivariate analysis: male sex, crackles, age ≥ 60 years, RF + , anti-CCP + . Range 0-11, cutoff value ≥ 5.5, AUC 0.80 (95% CI 0.70-0.89), Se 75%, and Sp 71%. When we added the LUS variable to this score: lines B ≥ 5, the range was 0-15, a cutoff value ≥ 7.5, AUC 0.88 (95% CI 0.81-0.94), Se improved to 84.4%, and Sp 75%. However, this last score did not exceed the performance of isolated LUS.
conclusionsLUS is a good tool for detecting ILD in patients with RA. Key Points • Interstitial lung disease (ILD) is an extra-musculoskeletal manifestation with high morbidity and mortality in patients with rheumatoid arthritis (RA). Early detection could improve the prognosis of these patients. • High-resolution chest tomography (HRCT) is the gold standard for ILD diagnosis, but high radiation and limited access hinder its use. • Lung ultrasound (LUS) is an excellent tool for detecting ILD in RA patients and performs better than clinical scores. • LUS provides a method of screening for ILD in patients with RA in a simple, cheap, safe, and effective way.
Indexed as
Identifiers
40555925What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.